Treatment Of Dysbiosis Research Articles

The addition of Lactobacillus spp. negatively affects Mycoplasma bovis viability in bovine cervical mucus

BackgroundMycoplasma bovis is an important pathogen for the cattle industry worldwide causing significant economic losses. Several transmission routes, including those related to reproduction, have been described. Indeed, the pathogen can colonize the female reproductive tract after artificial insemination (AI) with contaminated semen. Lactobacillus spp.-based probiotics have been used for vaginal dysbiosis treatment in women and cows although their role in controlling cervico-vaginal infections due to M. bovis is unknown. The objective of the present work is to assess the viability of M. bovis (PG45, NCTC 10131) in experimentally contaminated cervical mucus after the addition of Lactobacillus spp. at different concentrations as a competing agent and pH acidifier.ResultsThe addition of probiotic at a concentration higher than 108 colony forming units (CFU/mL had a detrimental effect (P < 0.05) on mycoplasma viability in cervical mucus. This coincided with a significant LAB growth and an important decrease in pH from 8.4 to 5.6 (P < 0.05). However, after the addition of less concentrated probiotic, M. bovis survival was not affected and there was no significant LAB growth despite the drop of pH from 8.4 to 6.73 (P < 0.05).ConclusionThe addition of concentrations higher than 108 CFU/mL of Lactobacillus spp. negatively affects M. bovis viability in bovine cervical mucus under in vitro conditions. Although the effect observed on the pathogen viability seems to be related to the pH decrease after LAB proliferation in cervical mucus, further studies are necessary to elucidate if other factors are implicated. Nevertheless, the administration of Lactobacillus spp.-based probiotics might be used in the future to control M. bovis proliferation in the cervico-vaginal tract of cows.

APPLICATION EFFICIENCY OF BIFIDOBACTERIUM BIFIDUM 1 AND LACTOBACILLUS REUTERI DSM 17938 CELL-FREE EXTRACTS IN VIVO

Insufficient efficiency and safety of cellular probiotics encourages the search for new effective means of correction of microecological disorders. Most of the beneficial effects of probiotics are due to the biological activity of their structural components and metabolites. Recently, great hope is pinned on postbiotic products as a means of restoring the balance of intestinal microbial populations. The data obtained in this experimental study demonstrate the ability of cell-free extracts from Bifidobacterium bifidum 1 and Lactobacillus reuteri DSM 17938 cultures, cultivated in their own disintegrates supplemented with ascorbic acid, to provide anti-infection protection and correct microecological disturbances at modeling an infectious process against a background of antibiotic-induced dysbiosis in mice. The beneficial effects of cell-free extracts showed up in the acceleration of the pathogen elimination and an increase in the number of representatives of the positive intestinal microbiota. The results of the study justify the need for further clinical trials to determine the therapeutic efficacy of cell-free extracts when included in the protocols of dysbiosis treatment.

The combination of mare's milk and grape polyphenol extract for treatment of dysbiosis induced by dextran sulfate sodium

Abstract. Kozhakhmetov S, Babenko D, Nurgaziyev M, Tuyakova A, Nurgozhina A, Muhanbetganov N, Chulenbayeva L, Sergazy S, Gulyayev A, Saliev T, Kushugulova A. 2020. The combination of mare's milk and grape polyphenol extract for treatment of dysbiosis induced by dextran sulfate sodium. Biodiversitas 21: 2275-2280. This study showed the potential of a biological product based on mare's milk and a complex of grape polyphenols to modulate intestinal microflora after dextran sulfate sodium (DSS)-induced dysbiosis. Rat ulcerative colitis has been developed using intra-gastric administration of 10% DSS solution. To track changes in the structure of the microbiome at all stages of the study, the next-generation sequencing of the 16S rRNA gene section and LotuS conveyor were used. The results of sequencing demonstrated a decrease in biological diversity of microbiota after the induction of colitis, and recovery after 7 days of use of the (MMGPE). The product induced the structural changes of the microbiome damaged by DSS. Representatives of SCFA producing bacteria increased concentrations of Prevotella, Alloprevotella, Lactobacillus, Ruminococcaceae, and Blautia.

Optimal approach to comprehensive treatment of mixed urogenital tract infections

Objective — to study the spectrum and frequency of detection of various urogenital infections in patients with inflam-matory diseases of the genitourinary tract; to determine the characteristics of clinical course, clinical and microbiological effect, safety and tolerability of Orcipol drug (tablets produced by Baili-Creat Laboratory — Verny, France; World Medicine company); to assess Breveluck probiotic (capsules produced by ADIFARM Ltd., Bulgaria; World Medicine company) in the restoration of normal biocenosis of the body after antibiotic therapy.Materials and methods. Outpatient treatment was conducted of 79 patients (36 women and 43 men) aged 18—45 years (average age — (31 ± 1.5) years) with various inflammatory diseases of the genitourinary tract caused by mixed urogenital infections.Results and discussion. During the bacteriological study, data were obtained indicating the frequent presence of anaerobic and aerobic pathogens in associations with chlamydia, mycoplasma and trichomonade infections. Thus, in 63 (79.8 %) patients was found Staphylococcus epidermidis, in 13 (16.5 %) — S. haemolyticus, in 51 (64.6 %) — Streptococcus spp., in 34 (43.1 %) — Staphylococcus aureus, in 19 (24.1 %) — Corynebacterium spp, in 16 (20.3 %) — Proteus mirabilis. All patients showed different associations of sexually transmitted infections and/or conditionally pathogenic flora in clinically significant titers (above 104 CFU/ml).Conclusions. According to studies, the combined antibacterial drug Orcipol (ciprofloxacin + ornidazole) in complex with the probiotic Breveluck is a rational and effective method of treatment of mixed infections of the genitourinary tract. The advantages of the drug are a wide range of antimicrobial effects, the ability to affect the atypical pathogens and the simplest, as well as the presence of a post-antibiotic effect. High clinical efficiency, good tolerability and low frequency of development of side effects make it possible to use the drug in outpatient conditions in short courses. All observed patients with lesions caused by different combinations of mixed genitourinary infection achieved a clinical recovery. The high rate of pathogen elimination (93.5%) achieved by using Orcipol and significant compliance allow us to recommend this drug for the treatment of mixed urinary tract infections. It is also rational to prescribe the probiotic Breveluck, effective for the prevention and treatment of dysbiosis.

Microbiome and hypertension: where are we now?

Hypertension is the leading risk factor for cardiovascular disease and accounts for approximately 9.4 million deaths globally every year. Hypertension is a complex entity, which is influenced by genetic and environmental factors, such as physical inactivity, obesity, alcohol consumption, tobacco use, stress, diet and why not the microbiome. We searched PubMed using the words 'microbiome', 'microbiota' and 'hypertension' until December 2018. We found information regarding the role of the brain-gut--bone marrow axis, the brain-gut--kidney axis, the high-salt diet, short-chain fatty acids (SCFAs), neurotransitters, such as serotonin, dopamine and norepinephrine, nitric oxide, endothelin and steroids in modulating gut microbiota and in contributing to the pathogenesis of hypertension. The brain--gut--bone marrow axis refers to the hypothesis that hematopoietic stem cells might migrate to the brain or to the gut, and thus, contribute to local inflammation and several immune responses. This migration may further enhance the sympathetic activity and contribute to blood pressure elevation. On the other hand, SCFAs, such as acetate and butyrate, have been shown to exert anti-inflammatory effects on myeloid and intestinal epithelial cells. Also, researchers have noted diminution in microbial richness and diversity in hypertensive patients as well as marked differences in circulating inflammatory cells in hypertensive patients, when compared with controls. In addition, activation of renal sympathetic nerve activity might directly influence renal physiology, by altering body fluid balance and plasma metabolite secretion and retention. These events culminate in the development of chronic kidney disease and hypertension. There is a long way ahead regarding the role of gut microbiota in the pathogenesis and as an adjunctive treatment of hypertension. Treatment of dysbiosis could be a useful therapeutic approach to add to traditional antihypertensive therapy. Manipulating gut microbiota using prebiotics and probiotics might prove a valuable tool to traditional antihypertensives.

Introduction of Probiotic Type of Yogurt for the Treatment of Dysbiosis of Patients with Lymphogranulomatosis Under Polychemotherapy by BEACOPP‑II Protocol

The efficacy of using probiotic preparations of the yogurt type was studied in 136 patients with lymphogranulomatosis, suffering from intestinal dysbiosis while taking antibiotic therapy and polychemotherapy (BEACOPP-II protocol). It was found that probiotics of this type are highly effective for the treatment of dysbiotic disorders of the intestines in cancer and hematological patients. Their use significantly reduces the risk of complications such as an unpleasant aftertaste in the mouth, belching, heartburn, diarrhea, constipation, flatulence, discomfort or periodic abdominal pain. It is recommended that prolonged therapy with a probiotic of the yogurt type be used in these groups of patients.

Introduction of Probiotic Type of Yogurt for the Treatment of Dysbiosis of Patients with Lymphogranulomatosis Under Polychemotherapy by BEACOPP‑II Protocol

Introduction of Probiotic Type of Yogurt for the Treatment of Dysbiosis of Patients with Lymphogranulomatosis Under Polychemotherapy by BEACOPP‑II Protocol

Lung microbiome - a modern knowledge.

Recent studies have reported that commensal microorganisms are not just “passive occupants” but may play a crucial role in the immune system activation. It is well-known that in critically ill patients, the microbiome is modified and may be associated with the development of immunosuppression in sepsis, contributing to the development of acute renal injury, cardiovascular diseases, or more importantly, respiratory system disturbances. The conviction of lung sterility has gone down in history. The presence of characteristic gut microbiome, such as Bacteroidetes and Enterobacteriaceae, was demonstrated in lungs of critically ill patients. This bacteria’s translocation, especially in ischemia-reperfusion injury, results in increased concentration of inflammation response markers and may play a pivotal role in the pathogenesis of respiratory system disturbances, including acute respiratory distress syndrome. Recent studies have shown that ischemia-reperfusion injury is often observed in intensive care units (ICUs) and predispose to microbiome disturbances that are strictly connected with immune system activation and epithelial damage. Potential effects of dysbiosis treatment are under highly activated investigation. Therefore, it is possible that microbiota-targeted therapy may constitute the future therapeutic path in ICUs.

Experimental treatment of dysbiosis in colitis with hepatitis

Experimental treatment of dysbiosis in colitis with hepatitis

Experimental treatment of dysbiosis in colitis with hepatitis

Nonspecific colitis (inflammation of the colon mucosa) is a common gastroenterological disease. The causative factors of this disease are intestinal dysbiosis, which leads to an increase in blood concentration of intestinal endotoxin (lipopolysaccharide), as well as impaired liver antimicrobial function.The purpose of this study was to determine the possibility of preventing colitis, which develops as a result of a combination of dysbiosis and hepatitis, with the help of biotrit, which has an antidysbiotic and hepatoprotective effect.The experiments were conducted on 24 white rats of the Wistar line (males, 1 month old), divided into 3 equal groups: 1 - control (normal); 2 - dysbiosis + hepatitis without treatment; 3 - dysbiosis + hepatitis + drug "Biotrit".Dysbiosis was caused by the antibiotic lincomycin, which was given to rats with drinking water at a dose of 60 mg / kg for the first 5 days. Toxic hepatitis was reproduced in rats using hydrazine hydrochloride.Studies have shown that the phytopreparation Biotrit has a mucosoprotective effect in experimental nonspecific colitis due to both antidysbiotic and antioxidant effects.

A whiff of change for dysbiosis treatment

Vaginal microbiome transplantation might be a safe and effective treatment in patients with intractable bacterial vaginosis.

Diagnóstico e tratamento da disbiose: Revisão Sistemática

Objetivo: Revisar a literatura a fim de reunir informações atualizadas quanto ao diagnóstico e às condutas terapêuticas disponíveis na disbiose intestinal. Métodos: Foram utilizadas informações obtidas a partir de buscas feitas nas bases de dados BIREME, LILACS, MEDLINE e PUBMED, utilizando como descritores os termos “Disbiose”, “Transplante de microbiota fecal” e “Síndrome disabsortiva”, com as opções em inglês, português, espanhol e francês, tendo sido empregado o boleano AND. Além disso, foram excluídos do trabalho os artigos publicados há mais de 6 anos, tendo sido encontrados 20 artigos aptos para serem abordados. Vale ressaltar que 18 artigos foram publicados nos últimos 5 anos e apenas 2 artigo foi publicado nos últimos 6 anos. Resultados: Foram coletados 20 artigos em que 9 autores discutiram sobre o tratamento com probióticos, 5 discutiram sobre o tratamento por meio do transplante da microbiota fecal, 5 autores discutiram sobre o tratamento da disbiose com prebióticos, 3 abordaram sobre o tratamento com antibióticos e 3 explicaram sobre o tratamento por meio da suplementação de glutamina. Conclusões: São necessárias maiores pesquisas e estudos sobre o tratamento utilizado na disbiose intestinal para que se tenha uma padronização da técnica.

The Microbiome and Atopic Dermatitis: A Review.

The microbiome is defined as the sum of microbes, their genomes, and interactions in a given ecological niche. Atopic dermatitis is a multifactorial chronic inflammatory skin disease leading to dryness and itchiness of the skin. It is often associated with comorbidities such as allergic rhinoconjunctivitis and asthma. Today, culture-free techniques have been established to define microbes and their genomes that may be both detrimental and beneficial for their host. There are signs that microbes, both on skin and in the gut, may influence the course of atopic dermatitis. Antiseptic treatment has been used for decades, however now, with the help of traditional culture-based methods and modern metagenomics, we are beginning to understand that targeted treatment of dysbiosis may possibly become part of an integrated therapy plan in the future.

PERIOPERATION CHANGES COLON AND RECTUM MICROBIOCINOSIS WITH COLORECTAL PATIENTS

Most colorectal cancer patients prove to have dysbiosis of varying severity. Perioperative period contributes to the progression of the microbiocenosis disorders. It has been proven that a large role in the development of postoperative complications is played by the state of the colon microflora. Materials. 211 colorectal cancer patient’s (T1-4N0-2M0) colon microflora was studied by PCR. Surgeries were performed laparoscopically. In the main group, developed diagnostic algorithm was used, in which initial colon flora was studied with dysbiosis progression risk determination by developed logistic regression model and perioperative correction of revealed disorders. Standards of dysbiosis treatment were used. Results. 100% patients in control group proved to have dysbiosis of varying severity: 1 grade - 27,4% (n=14), 2 grade - 37,3% (n=19), 3 grade - 31,4% (n=16), 4 grade - 3,9% (n=2). Dysbiosis progression was observed in postoperative period: 1 grade - 7,8% (n=4), 2 grade - 51,0% (n=26), 3 grade - 29,4% (n=15), 4 grade - 11,8% (n=6). The same preoperative results were registered in main group. However, after perioperative correction there was 12,5% (n=6) 3 grade and no registered 4 grade patients. Long-term results were better in the main group than in the control group. Adverse events were significantly higher in the control group against the main group (15,7% (n=8) and 4,2% (n=2) respectively). Discussion. We recommend preoperative stool analysis with PCR for colon microflora determination in order to further dysbiosis correction and treatment long-term results assessment.

Effect of Dahuang Danpi Decoction on Lactobacillus bulgaricus growth and metabolism: In vitro study.

Gut flora plays an essential role in disease and health. A traditional Chinese herb formula, Dahuang Danpi Decoction (DDD) can alleviate several gastrointestinal diseases.In the present study, we assessed the effect of DDD on the growth and metabolism of Lactobacillus bulgaricus. L bulgaricus was cultured in MRS with 40 mg/ml (high), 10 mg/ml (medium), and 2.5 mg/ml (low) of DDD, Ceftriaxone and blank (control). The growth of L bulgaricus was measured by optical density. The levels of L-lactic acid and D-lactic acid were also measured.Compared to the control group, the concentrations of L bulgaricus in the medium and the high concentrations DDD groups were significantly higher (P < .001 for all), while the concentrations of L bulgaricus in the ceftriaxone groups were significantly lower. In the 3 DDD groups, the L- lactic acid levels were significantly higher than those in the control group and the ceftriaxone groups (P < .001 for all), and the L-lactic acid level was the highest in the high DDD group. Similarly, the D-lactic acid level in the high concentration DDD group was significantly higher than those in the medium and low concentration DDD groups, the control group and the ceftriaxone groups. Both the L-lactic acid and D-lactic acid levels were lower than those in the control group and the DDD groups.DDD could dose-dependently promote the growth of L bulgaricus and enhance the secretion of L-lactic acid and D-lactic acid, which suggests DDD may be able to interact with the probiotics, improve the gut microbiota, and serve in the prevention and treatment of dysbiosis.

Систематический анализ исследований лактитола

Lactitol is a prebiotic disaccharide that supports the functioning of lacto- and bifidobacteria, also inhibits the growth of pathogenic flora. The results of transcriptome and proteomic studies have shown that lactitol is characterized by unique absorption and processing mechanisms in lactobacteriathat distinguish it from other prebiotics. In high doses (5 … 50 g/day) lactiol is used as an osmotic laxative. Lactictol enhances the detoxification of the body (in particular, the excretion of ammonia and toxic amines). The detoxification effect of lactitol, lack of lactitol’seffect on blood lipid and glycemic profiles, lack of food intolerance and rare occurrenceof side effects (flatulence, transient diarrhea when the dose is exceeded) make lactitol an important tool in the treatment of dysbiosis, liver disease and hepatic encephalopathy.

Bacillus amyloliquefaciens Ameliorates Dextran Sulfate Sodium-Induced Colitis by Improving Gut Microbial Dysbiosis in Mice Model.

Several Bacillus strains exert beneficial effects on the maintenance of intestinal homeostasis and host health. However, whether Bacillus amyloliquefaciens (BA) can improve gut microbial dysbiosis and ameliorate colitis is unknown. Therefore, we conducted the present study to investigate the effects of BA administration on intestinal morphology, inflammatory response, and colonic microbial composition in a mouse model of dextran sulfate sodium (DSS)-induced colitis. Results showed that BA administration significantly ameliorated body weight loss, decreased disease activity index, and improved colonic tissue morphology in DSS-treated mice. In addition, levels of immunoglobulins, as well as pro-inflammatory cytokines, were decreased after BA administration. Importantly, colonic microbiota profiling indicated a significant (p < 0.05) difference in beta-diversity between BA-administrated and DSS-treated mice, according to weighted principal coordinate analysis (PCoA) results. The relative abundance of the Firmicutes genus was increased, whereas that of Bacteroidetes was decreased by BA administration. Furthermore, phylogenetic investigation of communities by reconstruction of unobserved states (PICRUSt) analysis showed that the most significantly changed pathways between the four groups of mice were carbohydrate, lipid, and amino acid metabolism. In conclusion, our results showed that BA administration has beneficial effects on DSS-induced colitis, suggesting that this strategy might be useful for the treatment of dysbiosis during ulcerative colitis. Further, the changes in metabolism, especially amino acid metabolism, might contribute to the beneficial effects of BA on the amelioration of DSS-induced colitis.

Autoprobiotics as an Approach for Restoration of Personalised Microbiota.

Human microbiota is a complex consortium of microorganisms involved in the proper functioning of almost every system of the organism. Majority of the human diseases are associated with the development of intestinal dysbiosis. Dysbiotic condition or dysbiosis is a key pathogenic condition causing many severe infectious or non-infectious diseases. Rapid return to the original microbiota in many cases leads to the fast recovery from the disease. However, the optimal way of the treatment of dysbiosis is still under the discussion. Recently we have developed a method of autoprobiotics based on using isolated indigenous bacteria for improving of microbiota condition. The method based on feeding the patients with bacterial products grown from their personal, genetically characterised strains have been successfully tested in clinic on patients with IBS or chronic pneumonia. In present study we tried to evaluate technology employing autoprobiotic bacteria belonging to different species employing the rat model of antibiotic induced dysbiosis. Six experimental groups of animals after taking antibiotics were treated with different variants of autoprobiotics (lactobacillus, bifidobacteria, enterococcus, their mixture, fecal microbiota, or anaerobically grown complex of indigenous microbiota) prepared for each of them before the development of dysbiosis. Judging by the multiple parameters including metagenomics analysis of microbiota, immune status and microbiota content of the animals with dysbiosis relatively to control group, the most pronounced positive changes were provided by autoprobiotics based on enterococci, bifidobacteria or the consortium of indigenous bacteria grown under anaerobic conditions. These groups of autoprobiotics were delivering the most effective restoration of the original microbiota content and significant anti-inflammatory reaction of the immune system.

Dysbiosis in Children Born by Caesarean Section

The rate of Caesarean-section delivery in the United States has increased by 60% from 1996 through to 2013 and now accounts for > 30% of births [CDC, 2017]. The purpose of this review is to present the current understanding of both the microbial risk factors that increase the likelihood of a Caesarean-section delivery and the microbial dysbiosis that is thought to result from the Caesarean section. We provide examples of research into the impact of early-life microbial dysbiosis on infant development and long-term health outcomes, as well as consider the efficacy and the long-term implications of microbiome-based therapies to mitigate this dysbiosis. The steep rise in the Caesarean-section delivery rate makes it imperative to understand the potential of microbiota modulation for the treatment of dysbiosis.

Personalized Probiotics Based on Phenotypes and Dietary Habit: A Critical Evaluation

It is now established that probiotics are strain-dependent, to further advance the concept of probiotic in the maintenance of health and treatment of dysbiosis, the scope of personalized probiotics need to be defined. Currently, probiotic products are marketed worldwide, with the assumption that probiotics with demonstrated health effects work on all people, irrespective of the genetic (ethnicity), environment (geographical location), dietary habit and life style. The effectiveness of probiotics are determined by 1) interactions with prevailing gastrointestinal (GI) commensal microbes, in promoting the establishment of beneficial microbes and elimination of pathogens, 2) Interaction with the host, in achieving a desirable probiotic effect, 3) Interaction with diet, to survive, proliferate and colonize GI, albeit temporary, and in the production of beneficial bioactive metabolites, such as short-chain-fatty acids (e.g. butyric acid), bile acid derivatives and trimethylamines. The benefits acquired from a probiotic are personal, depending on the health status, dietary habit and prevailing GI microbiota. Personalized probiotics should be established to achieve precision administration of specific probiotic effects for targeted population. Globalization and urbanization of human activities have led to merging of dietary habit, thus effective probiotics should evolve in tandem. Ultimately the probiotics of choice should be directed at specific physiological stage, health condition and targeted diseases.